Egypt's 2025 Tax Reforms: The Compliance Reset Facing Pharmaceutical Manufacturers and Distributors

Pharmaceutical businesses in Egypt entered 2025 facing the busiest stretch of tax legislation in years. A run of statutes and executive decrees has reshaped how companies register, invoice, recover input tax, and close historic disputes. The headline exemption on medicines survives intact, but the compliance machinery around it has moved in ways that matter to manufacturers, importers, and distributors alike.

The exemption is the right starting point. Locally produced and imported medicines, along with the materials used to make them, have sat outside value added tax since the 2016 VAT statute, with the scope of exempt inputs anchored to decisions of the Egyptian Drug Authority. That treatment has not been touched. The familiar consequence, however, persists: because medicine supplies are exempt rather than zero-rated, input VAT on taxable costs such as packaging, equipment, logistics, and professional fees generally cannot be recovered and instead lodges in the cost base. Precise cost allocation and disciplined supplier records are therefore a standing requirement for the sector, not an afterthought.

The February 2025 package delivered three facilitation laws that every pharmaceutical group should have assessed. Law No. 5 of 2025 let previously unregistered businesses bring their status into order with the Tax Authority free of back taxes or penalties, provided they registered within the statutory window, which closed in August. For supply chains that lean on a long tail of smaller distributors, wholesalers, and service providers, this amnesty carried weight, because the formality of those counterparties feeds directly into a company's own documentation and deductibility. Law No. 6 of 2025 created a simplified regime for enterprises turning over up to twenty million Egyptian pounds, with rates scaled to revenue and relief from stamp duty, capital gains tax, and dividend distribution tax. Smaller pharmacies, contract service providers, and emerging local players may sit inside this bracket and should model whether electing in is worthwhile. Law No. 7 of 2025 reworked tax procedures, capping late-payment additions at one hundred percent of the original tax and opening settlement routes for non-payment offences. For groups carrying legacy assessments, that settlement path offers a way to quantify and close exposure.

The most consequential shift for day-to-day compliance is the continued widening of mandatory electronic invoicing and receipts. E-invoices are the only support the Authority treats as valid for deductible costs, and further taxpayer groups were pulled into the system through 2025, including expanded business-to-consumer e-receipt duties. Under Resolution No. 281 of 2025, certain Cairo-registered taxpayers had to begin issuing e-receipts for B2C transactions from 15 September 2025. The point is easy to miss in an exempt sector: although medicines carry no output VAT, pharmaceutical companies remain fully inside the e-invoicing net for corporate income tax and for any taxable supplies they make. A manufacturer that cannot evidence its costs on compliant e-invoices risks losing those deductions in its corporate tax return regardless of its exempt output profile.

Later in the year the VAT framework itself was amended. Law No. 157 of 2025, effective 18 July 2025, broadened the base and brought new items into charge, and Ministerial Decree No. 417, issued in December 2025, amended the executive regulations to refine definitions and align them with the statute. Recovery of input VAT on inventory remains available where backed by a valid e-invoice or proper customs documentation. Importers should read these refinements closely, because imported inputs, the line between exempt and taxable activity inside one group, and the documentary conditions for any recovery are exactly where the sector's exempt status produces complexity rather than ease.

Genuine incentives are also on the table. Under the investment incentive framework, projects established outside the most developed areas can deduct a share of investment costs, set at thirty percent, from net taxable profit, and industrial activity of the kind run by pharmaceutical manufacturers can fall within scope. Companies planning new lines or capacity should structure those investments deliberately to land inside the incentive perimeter rather than discovering the conditions after the fact.

The regional comparison reinforces the theme. In the United Arab Emirates, a qualifying free zone person can still reach a zero percent corporate tax rate on qualifying income, but must now prepare audited financial statements to substantiate the split between qualifying and non-qualifying income. The trajectory in both jurisdictions is the same: incentives endure, yet they are increasingly gated behind rigorous, auditable records. For pharmaceutical groups, the practical message is consistent. Substance, documentation, and disciplined e-invoicing now decide whether the sector's favourable treatment is realised in practice or quietly forfeited.